Robert Nelsen

Robert Nelsen is a co-founder and Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150 companies, including over 50 early stage investments that have reached valuations exceeding $1 billion. Mr. Nelsen is focused on disruptive technologies or business models and partnering with founding management teams and entrepreneurs to execute on these visions by advancing novel platform technologies. Some of his notable early-stage investments include “Project Prometheus,” Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), Juno Therapeutics (JUNO-acquired by Celgene), Impinj (PI), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX-acquired by Bristol-Myers Squibb), Altos Labs, National Resilience, Xaira Therapeutics, Insitro, Colossal Biosciences, Prime Medicine (PRME), Lyell Immunopharma (LYEL), Array BioPharma (ARRY-acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Seaport Therapeutics, Maze Therapeutics (MAZE), Rapport Therapeutics (RAPP), EQRx (EQRX – acquired by Revolution Medicines), Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina-GRAL), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH-acquired by Allergan, Receptos (RCPT-acquired by Celgene), Aviron (AVIR-acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (acquired by Eli Lilly), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acqui